Clinical trials currently recruiting patients in the Bay Area are listed below. Please use this list to identify trials that may be of interest to your patients. If you have information regarding other clinical trials that are open for recruitment and that you would like to add, please contact us at info@sfderm.org

National Institute of Health:

The NIH is conducting a phase 2 clinical trial using IL-1 receptor antagonist anakinra to treat pustular dermatoses including, but not limited to, generalized pustular psoriasis and palmoplantar pustulosis
http://clinicaltrials.gov/show/NCT01794117

Private Practice:

A phase 3 randomized, double blinded placebo controlled clinical study to evaluate a systemic drug in patients 12 and over with severe Acne Vulgaris
Principal investigator- Sunil S. Dhawan, MD Contact: 510-797-0140 x6 or at clinicalresearch@ctr4derm.com for inquiries
A phase 3 randomized, double-Blinded Placebo controlled clinical study to evaluate a cream in adult subjects with Actinic Keratosis on the face and scalp
Principal investigator- Sunil S. Dhawan, MD Contact: 510-797-0140 x6 or at clinicalresearch@ctr4derm.com for inquiries
A phase 3 randomized, double –blinded placebo controlled clinical study to evaluate a systemic drug in adult subjects with severe Atopic Dermatitis
Principal investigator- Sunil S. Dhawan, MD Contact: 510-797-0140 x6 or at clinicalresearch@ctr4derm.com for inquiries

A phase 3 randomized, double –blinded placebo controlled clinical study to evaluate a systemic drug in pediatric subjects with severe Atopic Dermatitis.
Principal investigator: Jeff Sugarman, MD
Contact Liza Marie and Kim Witt at (707) 755-3946
Redwood Dermatology Research. 2725 Mendocino Ave, Santa Rosa CA 95403.

Ongoing studying, specifically collecting BCC samples to try some new approaches to growing these cells in vitro. More generally in knowing the number of BCNS patients locally
Principal Investigator – Ervin Epstein, MD Contact : 510-450-5688 or eepstein@chori.org for inquiries
Psoriasis

A phase 3 randomized , double blinded placebo controlled clinical study to evaluate a cream in adult subjects with Psoriasis
Principal Investigator – Sunil S. Dhawan, MD Contact : 510-797-0140 x 6 or clinicalresearch@ctr4derm.com for inquiries

Two phase 3 randomized, double blinded placebo controlled clinical studies to evaluate an oral and systemic drug in adult patients with severe PsoriasisPrincipal investigator- Sunil S. Dhawan, MD Contact: 510-797-0140 x6 or at clinicalresearch@ctr4derm.comfor inquiries

Stanford

Tofacitinib for the Treatment of Alopecia Areata and Its Variants Principal Investigator: Anthony E Oro, MD Contact: Milene Crispin, MD at (603) 667-1310

A Phase Ib Open-Label Study of Pembrolizumab (Keytruda, MK-3475) in Unresectable or Metastatic Basal Cell Carcinoma; NCT02690948- Therapeutic – immunotherapy –anti-PD-1
Principal investigator: Anne Chang MD Contact at alschang@stanford.edu or (650) 644-7318

Pembrolizumab with and without vismodegib for unresectable or metastatic basal cell carcinoma
Principal investigator: Anne Chang MD Contact at alschang@stanford.edu or (650) 644-7318

E Phase II Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death 1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma; NCT02760498
Principal investigator: Anne Chang MD Contact at alschang@stanford.edu or (650) 644-7318

Regeneron 2810 a PD1 inhibitor for unresectable or metastatic cutaneous squamous cell carcinoma
Principal investigator: Anne Chang MD Contact at alschang@stanford.edu or (650) 644-7318

Exploratory Pilot Study of Brentuximab Vedotin (SGN-35) in Patients with Mycosis Fungoides and Sezary Syndrome with Variable CD30 Expression Level Principal Investigator: Youn Kim MD Contact at younkim@stanford.edu

Protocol Title: An Open-Label, Treatment-Option Protocol of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma, or CD30-Positive Cutaneous T-Cell Lymphoma Principal Investigator: Youn Kim MD Contact at younkim@stanford.edu

Protocol Title: A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sézary Syndrome Principal Investigator: Youn Kim MD Contact at younkim@stanford.edu

A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma Contact Jennifer Vargas at (650)723-0371

A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults With Advanced Solid Tumors: Melanoma, Renal Cell, Non-small Cell Lung and Squamous Cell Head and Neck Cancer Contact Brenda Hann at (650) 723-0966

A Pilot Study of Ipilimumab in Subjects With Stage IV Melanoma Receiving Palliative Radiation Therapy Principal Investigator: Susan Knox Contact Chuck Di Bari at (650) 498-4073

BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma Principal Investigator: Branimir I. Sikic, MD Contact Jennifer Vargas at (650) 723-0371

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers Principal Investigator: Branimir I. Sikic, MD Contact Jennifer Vargas at (650) 723-0371

A Phase 1/2 Study to Evaluate MEDI4736 Contact Melanie San Pedro-Salcedo at (650) 724-1388

A double blind, randomized, placebo-controlled study to evaluate safety, tolerability,efficacy and preliminary dose-response of BAF312 in patients with active dermatomyositis
Clinical Research Coordinator: Saranya Preeya Nandagopal Contact at saranya@stanford.edu

A phase II study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis--a double-blind, placebo-controlled, randomized controlled trial Clinical Research Coordinator: Saranya Preeya Nandagopal Contact at saranya@stanford.edu

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) Clinical Research Coordinator: Saranya Preeya Nandagopal Contact at saranya@stanford.edu

The Natural History and Outcome of Scleroderma Patients at High Risk or with Early Pulmonary Hypertension (Pharos) (Observational Study) Contact: Amanda Foster at amfoster@stanford.edu or (650) 721-7147 Saranya Preeya Nandagopal saranya@stanford.edu or (650) 721-7163

Observational study of early diffuse cutaneous systemic sclerosis (ESOS) Contact: Amanda Foster at amfoster@stanford.edu or (650) 721-7147 Saranya Preeya Nandagopal saranya@stanford.edu or (650) 721-7163

The Scleroderma Patient- Centered Intervention Network (SPIN) Purpose: to develop a patient cohort that can be used to collect data that will provide important information on problems faced by people living with Systemic Sclerosis. (Observational Study) Contact: Amanda Foster at amfoster@stanford.edu or (650) 721-7147 Saranya Preeya Nandagopal saranya@stanford.eduor (650) 721-7163

Validation of Outcome Measures in Scleroderma-Associated Gastrointestinal Involvement Registry (GI Study) Purpose: The overall goal of this application is to validate outcome measures for clinical trials in Scleroderma-associated GI involvement. (Observational Study) Contact: Amanda Foster at amfoster@stanford.edu or (650) 721-7147 Saranya Preeya Nandagopal saranya@stanford.edu or (650) 721-7163

SSc Clinical Repository (sCar) Purpose: We are looking for abnormalities in the blood and skin that are associated with the development of scleroderma complications in order to better treat patients with Systemic Sclerosis (SSc). (Observational Study) Contact: Amanda Foster at amfoster@stanford.edu or (650) 721-7147 Saranya Preeya Nandagopal saranya@stanford.eduor (650) 721-7163

Skin Biopsies as Biomarkers of Systemic Sclerosis (SSc) and Response to Mycophenolate Mofetil (CellCept)(Observational Study) Contact: Amanda Foster at amfoster@stanford.edu or (650) 721-7147 Saranya Preeya Nandagopal saranya@stanford.edu or (650) 721-7163

Rituximab for Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (PAH) Purpose: To evaluate whether rituximab in combination with PAH medications improves PAH in patients with Systemic Sclerosis. Contact: Amanda Foster at samfoster@stanford.edu or (650) 721-7147 Saranya Preeya Nandagopal saranya@stanford.edu or (650) 721-7163

Genetic Basis of Rosacea

We are recruiting participants that are of European descent and have rosacea and are older than 30 years of age. We are also looking for healthy patients of European descent over the age of 60.

Principal investigator: Anne Chang, MD Contact at alschang@stanford.edu or (650) 644-7318

Discovery of Effects of Retinol on Human Skin Aging in Individuals of East Asian Descent

We are recruiting healthy volunteers of Han Chinese, Korean, and Japanese descent ages 18-25 or ages 55-75.

Principal investigator: Anne Chang, MD Contact at alschang@stanford.edu or (650) 644-7318

University of California, Davis

Lipidome and microbiomne profile of human skin and associated conditions.
Principal Investigator: Raja Sivamani MD, Contact Iryna Rybak at (916) 734-1509 or irybak@ucdavis.edu
1. Comparison of the cosmetic Effects of Bakuchiol and Retinol
Contact Simran Dhaliwal, Jr. Specialst at (916) 734-6556
2. The effect of Almonds on Skin Lipids and Wrinkles.
Contact Iryna Rybak at (916) 734-1509 or irybak@ucdavis.edu

Principal Investigator: Raja Sivamani MD
Characterization of The Melanoma – Specific Immune Response
Principal Investigator: Emanual Maverakis, M.D. Contact Hawa Sultani, CRC at hsultani@ucdavis.edu or (916) 734-1267
Genetic basis of Melanocytic Nevi
Principal Investigator: Maija Kiuru, MD, PhD, M.D. Contact Iryna Rybak, at irybak@ucdavis.edu or (916) 734-1509

A Phase III Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Principal Investigator: Emanual Maverakis, M.D. Contact Victoria Wells at dermstudies@ucdavis.edu or (916) 734-1267

Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease (The VIP Trial) Comparing Adalimumab/Humira/UVB Phototherapy
Principal Investigator: Victoria Sharon M.D. Contact Victoria Wells at dermstudies@ucdavis.edu or (916) 734-1267

A Randomized, Double-Blind, Double-Dummy, Active-Comparator, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil In Patients with Pemphigus Vulgaris
Principal Investigator: Emanual Maverakis, M.D.
Contact Victoria Wells at dermstudies@ucdavis.edu or (916) 734-1267 Forum Patel, M.D. at dpatelforumb@gmail.com or (916) 734-1512 Reason Wilken, M.D. at reason.wilken@ucdmc.ucdavis.edu or (916) 734-6760

Pilot study for the use of Photodynamic Therapy in the treatment of Seborrheic Dermatitis
Principal Investigator: Nasim Fazel, M.D., DDS, MAS
Contact Parastoo Davari, MD at pdavari@ucdavis.edu or (916) 734-6760

Elucidation of the mechanism of action of Xolair (omalizumab) in chronic idiopathic Uticaria

Prinical Investigator: Fu-Tong Lku, M.D, Ph.D.


Contact:Simran Dhaliwal Jr., Specialist or TSimran Dhaliwal Jr. (916) 734-6556

University of California, San Francisco:

CHR #16-19381: Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of Actinic Keratosis on the Face in Solid Organ Transplant Recipients (NCT02866995)

Contact:Christine.Kembikian@ucsf.edu or at (415) 353-9684

CHR #16-21068: A randomized, Double-Blind, Placebo-Controlled Study of the efficacy, safety, and tolerability of Serlopitant for the treatment of Pruritus in adults and adolescents with a history of Atopic Dermantitis. Contact: Christine.Kembikian@ucsf.edu or at (415) 353-9684

Imaging of systemic Kaposis sarcoma with Lymphoseek
Principal investigator: Toby Maurer MD
Contact at maurert@derm.ucsf.edu or (415) 206-8680

Recalcitrant Kaposis sarcoma-clinical trials through the AIDS Malignancy Consortium.
For Bay Area participants contact Toby Maurer MD Contact at maurert@derm.ucsf.edu or (415) 206-8680</a>

Squamous cell carcinoma in HIV infected patients-the role of HPV and immuunosenescence in primary and recurrent SCC's.
Principal investigator: Toby Maurer MD
Contact at maurert@derm.ucsf.edu or (415) 206-8680

CHR #14-15258: A Randomized, Double-Blind, Double Dummy, Active-Comparator, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris. (NCT02383589)
Contact: Christine.Kembikian@ucsf.edu or at (415) 353-9684

</p>

LOTUS: Longitudinal Trial to Understand Symptomology in Prurigo Nodularis

An observational year long stud of patients over 18 with Prurigo Nodularis, willing to participate in photography, biopsies, and itch diary. There is compensation of up to $500 for participation.

Prinical Investigator: Timothy Berger, MD


Contact:Brian Lu or Tim Berger (415) 353-7888

Elucidation of the mechanism of action of Xolair (omalizumab) in chronic idiopathic Uticaria

Prinical Investigator: Fu-Tong Lku, M.D, Ph.D.


Contact:Simran Dhaliwal Jr., Specialist or TSimran Dhaliwal Jr. (916) 734-6556 </p>
Updated October 2017